Ultragenyx adds new CMO with internal promotion; Autolus CFO to leave for MorphoSys — but not quite yet
As Ultragenyx looks to use the accelerated approval pathway for an increasing number of rare disease drugs, the company has promoted Eric Crombez to EVP and chief medical officer, effective May 1.
Crombez, who previously served as CMO for gene therapy and inborn errors of metabolism, joined Ultragenyx following its $138 million acquisition of Dimension Therapeutics in November 2017. Since January 2020, he’s also served in a non-voting role as industry representative on the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
